Application of Magnetocardiography to Screen for Inflammatory Cardiomyopathy and Monitor Treatment Response
BACKGROUND: Inflammatory cardiomyopathy is one of the most common causes of sudden cardiac death in young adults. Diagnosis of inflammatory cardiomyopathy remains challenging, and better monitoring tools are needed. We present magnetocardiography as a method to diagnose myocardial inflammation and m...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111485/ https://www.ncbi.nlm.nih.gov/pubmed/36744683 http://dx.doi.org/10.1161/JAHA.122.027619 |
_version_ | 1785027464553037824 |
---|---|
author | Brala, Debora Thevathasan, Tharusan Grahl, Simon Barrow, Steve Violano, Michele Bergs, Hendrikje Golpour, Ainoosh Suwalski, Phillip Poller, Wolfgang Skurk, Carsten Landmesser, Ulf Heidecker, Bettina |
author_facet | Brala, Debora Thevathasan, Tharusan Grahl, Simon Barrow, Steve Violano, Michele Bergs, Hendrikje Golpour, Ainoosh Suwalski, Phillip Poller, Wolfgang Skurk, Carsten Landmesser, Ulf Heidecker, Bettina |
author_sort | Brala, Debora |
collection | PubMed |
description | BACKGROUND: Inflammatory cardiomyopathy is one of the most common causes of sudden cardiac death in young adults. Diagnosis of inflammatory cardiomyopathy remains challenging, and better monitoring tools are needed. We present magnetocardiography as a method to diagnose myocardial inflammation and monitor treatment response. METHODS AND RESULTS: A total of 233 patients were enrolled, with a mean age of 45 (±18) years, and 105 (45%) were women. The primary analysis included 209 adult subjects, of whom 66 (32%) were diagnosed with inflammatory cardiomyopathy, 17 (8%) were diagnosed with cardiac amyloidosis, and 35 (17%) were diagnosed with other types of nonischemic cardiomyopathy; 91 (44%) did not have cardiomyopathy. The second analysis included 13 patients with inflammatory cardiomyopathy who underwent immunosuppressive therapy after baseline magnetocardiography measurement. Finally, diagnostic accuracy of magnetocardiography was tested in 3 independent cohorts (total n=23) and 1 patient, who developed vaccine‐related myocarditis. First, we identified a magnetocardiography vector to differentiate between patients with cardiomyopathy versus patients without cardiomyopathy (vector of ≥0.051; sensitivity, 0.59; specificity, 0.95; positive predictive value, 93%; and negative predictive value, 64%). All patients with inflammatory cardiomyopathy, including a patient with mRNA vaccine‐related myocarditis, had a magnetocardiography vector ≥0.051. Second, we evaluated the ability of the magnetocardiography vector to reflect treatment response. We observed a decrease of the pathologic magnetocardiography vector toward normal in all 13 patients who were clinically improving under immunosuppressive therapy. Magnetocardiography detected treatment response as early as day 7, whereas echocardiographic detection of treatment response occurred after 1 month. The magnetocardiography vector decreased from 0.10 at baseline to 0.07 within 7 days (P=0.010) and to 0.03 within 30 days (P<0.001). After 30 days, left ventricular ejection fraction improved from 42.2% at baseline to 53.8% (P<0.001). CONCLUSIONS: Magnetocardiography has the potential to be used for diagnostic screening and to monitor early treatment response. The method is valuable in inflammatory cardiomyopathy, where there is a major unmet need for early diagnosis and monitoring response to immunosuppressive therapy. |
format | Online Article Text |
id | pubmed-10111485 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101114852023-04-19 Application of Magnetocardiography to Screen for Inflammatory Cardiomyopathy and Monitor Treatment Response Brala, Debora Thevathasan, Tharusan Grahl, Simon Barrow, Steve Violano, Michele Bergs, Hendrikje Golpour, Ainoosh Suwalski, Phillip Poller, Wolfgang Skurk, Carsten Landmesser, Ulf Heidecker, Bettina J Am Heart Assoc Original Research BACKGROUND: Inflammatory cardiomyopathy is one of the most common causes of sudden cardiac death in young adults. Diagnosis of inflammatory cardiomyopathy remains challenging, and better monitoring tools are needed. We present magnetocardiography as a method to diagnose myocardial inflammation and monitor treatment response. METHODS AND RESULTS: A total of 233 patients were enrolled, with a mean age of 45 (±18) years, and 105 (45%) were women. The primary analysis included 209 adult subjects, of whom 66 (32%) were diagnosed with inflammatory cardiomyopathy, 17 (8%) were diagnosed with cardiac amyloidosis, and 35 (17%) were diagnosed with other types of nonischemic cardiomyopathy; 91 (44%) did not have cardiomyopathy. The second analysis included 13 patients with inflammatory cardiomyopathy who underwent immunosuppressive therapy after baseline magnetocardiography measurement. Finally, diagnostic accuracy of magnetocardiography was tested in 3 independent cohorts (total n=23) and 1 patient, who developed vaccine‐related myocarditis. First, we identified a magnetocardiography vector to differentiate between patients with cardiomyopathy versus patients without cardiomyopathy (vector of ≥0.051; sensitivity, 0.59; specificity, 0.95; positive predictive value, 93%; and negative predictive value, 64%). All patients with inflammatory cardiomyopathy, including a patient with mRNA vaccine‐related myocarditis, had a magnetocardiography vector ≥0.051. Second, we evaluated the ability of the magnetocardiography vector to reflect treatment response. We observed a decrease of the pathologic magnetocardiography vector toward normal in all 13 patients who were clinically improving under immunosuppressive therapy. Magnetocardiography detected treatment response as early as day 7, whereas echocardiographic detection of treatment response occurred after 1 month. The magnetocardiography vector decreased from 0.10 at baseline to 0.07 within 7 days (P=0.010) and to 0.03 within 30 days (P<0.001). After 30 days, left ventricular ejection fraction improved from 42.2% at baseline to 53.8% (P<0.001). CONCLUSIONS: Magnetocardiography has the potential to be used for diagnostic screening and to monitor early treatment response. The method is valuable in inflammatory cardiomyopathy, where there is a major unmet need for early diagnosis and monitoring response to immunosuppressive therapy. John Wiley and Sons Inc. 2023-02-06 /pmc/articles/PMC10111485/ /pubmed/36744683 http://dx.doi.org/10.1161/JAHA.122.027619 Text en © 2023 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Research Brala, Debora Thevathasan, Tharusan Grahl, Simon Barrow, Steve Violano, Michele Bergs, Hendrikje Golpour, Ainoosh Suwalski, Phillip Poller, Wolfgang Skurk, Carsten Landmesser, Ulf Heidecker, Bettina Application of Magnetocardiography to Screen for Inflammatory Cardiomyopathy and Monitor Treatment Response |
title | Application of Magnetocardiography to Screen for Inflammatory Cardiomyopathy and Monitor Treatment Response |
title_full | Application of Magnetocardiography to Screen for Inflammatory Cardiomyopathy and Monitor Treatment Response |
title_fullStr | Application of Magnetocardiography to Screen for Inflammatory Cardiomyopathy and Monitor Treatment Response |
title_full_unstemmed | Application of Magnetocardiography to Screen for Inflammatory Cardiomyopathy and Monitor Treatment Response |
title_short | Application of Magnetocardiography to Screen for Inflammatory Cardiomyopathy and Monitor Treatment Response |
title_sort | application of magnetocardiography to screen for inflammatory cardiomyopathy and monitor treatment response |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111485/ https://www.ncbi.nlm.nih.gov/pubmed/36744683 http://dx.doi.org/10.1161/JAHA.122.027619 |
work_keys_str_mv | AT braladebora applicationofmagnetocardiographytoscreenforinflammatorycardiomyopathyandmonitortreatmentresponse AT thevathasantharusan applicationofmagnetocardiographytoscreenforinflammatorycardiomyopathyandmonitortreatmentresponse AT grahlsimon applicationofmagnetocardiographytoscreenforinflammatorycardiomyopathyandmonitortreatmentresponse AT barrowsteve applicationofmagnetocardiographytoscreenforinflammatorycardiomyopathyandmonitortreatmentresponse AT violanomichele applicationofmagnetocardiographytoscreenforinflammatorycardiomyopathyandmonitortreatmentresponse AT bergshendrikje applicationofmagnetocardiographytoscreenforinflammatorycardiomyopathyandmonitortreatmentresponse AT golpourainoosh applicationofmagnetocardiographytoscreenforinflammatorycardiomyopathyandmonitortreatmentresponse AT suwalskiphillip applicationofmagnetocardiographytoscreenforinflammatorycardiomyopathyandmonitortreatmentresponse AT pollerwolfgang applicationofmagnetocardiographytoscreenforinflammatorycardiomyopathyandmonitortreatmentresponse AT skurkcarsten applicationofmagnetocardiographytoscreenforinflammatorycardiomyopathyandmonitortreatmentresponse AT landmesserulf applicationofmagnetocardiographytoscreenforinflammatorycardiomyopathyandmonitortreatmentresponse AT heideckerbettina applicationofmagnetocardiographytoscreenforinflammatorycardiomyopathyandmonitortreatmentresponse |